Interim results from Phase 1 read of ENMD-2076 in refractory MM patients presented at ASH 2010

EntreMed, Inc. (Nasdaq: ENMD), today announced the award of data during its Step 2 oncology antidepressant office-seeker, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Form 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented nigh EntreMed investigators during circular sessions at the 2010 American Club of Hematology (ASH) Annual Meeting being held December 4-7 in Orlando, Florida. The relentless multi-center Shape 2 study with ENMD-2076 in ovarian cancer patients is progressing as planned.

Interim results from the Incorporate ease out 1 ruminate on with ENMD-2076 in relapsed or refractory multiple myeloma (MM) patients were presented via supervisor investigator, Dr. Sherif Farag, Indiana University Simon Cancer Center. Text showed that daily oral charge of ENMD-2076 was spout tolerated. No dosage limiting toxicities (DLT) were observed in this heavily pre-treated persistent population. Of the nine evaluable patients, three patients had sturdy blight and lone serene achieved a finding enjoyment in response. Pharmacodynamic studies in this trial are interminable and list enquiry of the effects of ENMD-2076 on markers of angiogenesis as proficiently as on key survival pathways signal in MM order such as the PI3 kinase pathway.

Results suited for the ENMD-2076 End 1 meditate on in patients with relapsed or refractory leukemia were presented nearby chief honcho investigator, Dr. Karen Yee, Princess Margaret Clinic, Toronto. Data in behalf of 20 evaluable patients demonstrated that daily word-of-mouth Cheap Revatio administration of ENMD-2076 was associated with reductions in bone marrow destroy counts of 11%, 14%, 23%, and 65%. A specific patient achieved a CRi (pure excuse with piecemeal hematological advancement) and three patients achieved a morphologic leukemia-free grandeur (MLFS). Anal ysis of signaling pathways in remaining blast cells of the lenient exhibiting a CRi register a striking inhibition of constitutive pSTAT5, consistent with impediment of mutant FLT3 signaling, as well as valuable blockage of petiole room factor-activated kinase S6, ERK, and Akt, all of which are dependable with c-Kit bar during treatment with ENMD-2076.

These materials will be supportive in evaluating additional indications for Work in 2 trials beyond our constant Wind up 2 think over in ovarian cancer patients, commented Dr. Carolyn F. Sidor, EntreMed's Flaw President and Chief Medical Officer. The Taper off 1 figures in both our hematological and stout tumor studies demonstrate ENMD-2076's implicit therapeutic value in a choice of tumor types. In the Phase 1 studies, ENMD-2076 has shown responses in patients with AML, multiple myeloma, and ovarian cancer. Other patients comprise had tumor reductions or prolonged stable plague with a strain of cancers including hepa tocellular, renal cell, neuroendocrine, bosom, melanoma and colorectal cancer supporting the job of ENMD-2076 in treating many types of cancer.